Novo Nordisk trades at a significant discount to Eli Lilly, offering nearly 38% upside. Click here to find out why NVO stock ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

Ongoing patent battle between Novo Nordisk and Dr Reddy’s Laboratories over semaglutide export to multiple countries.

Semaglutide, a GLP-1R agonist developed by Denmark’s Novo Nordisk as Ozempic, initially for type 2 diabetes, and marketed ...

What happens when you stop taking Ozempic®? There’s no one-size-fits-all answer to this question. When you stop taking ...

Eating disorder centers are facing an influx of people with weight-loss prescriptions. Experts say doctors are ...

More than 80 U.S. lawmakers asked the FDA to stop counterfeit GLP-1 drugs linked to Chinese suppliers from entering the ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

Ozempic and Mounjaro are both very popular for weight loss at the minute, but there's one big difference between the two ...

Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid ...